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Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by inflammation of enthe-
ses and synovium, leading to joint erosions and new bone formation. It affects 10–30% 
of patients with psoriasis, and has an estimated prevalence of approximately 1%. PsA is 
considered to be primarily an autoimmune disease, driven by autoreactive T cells directed 
against autoantigens present in the skin and in the joints. However, an autoinflammatory 
origin has recently been proposed. Long noncoding RNAs (lncRNAs) are RNAs more than 
200 nucleotides in length that do not encode proteins. LncRNAs play important roles in 
several biological processes, including chromatin remodeling, transcription control, and 
post-transcriptional processing. Several studies have shown that lncRNAs are expressed 
in a stage-specific or lineage-specific manner in immune cells that have a role in the 
development, activation, and effector functions of immune cells. LncRNAs are thought to 
play a role in several diseases, including autoimmune disorders. Indeed, a few lncRNAs 
have been identified in systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. 
Although several high-throughput studies have been performed to identify lncRNAs, their 
biological and pathological relevance are still unknown, and most transcriptome studies 
in autoimmune diseases have only assessed protein-coding transcripts. No data are 
currently available on lncRNAs in PsA. Therefore, by microarray analysis, we have investi-
gated the expression profiles of more than 50,000 human lncRNAs in blood samples from 
PsA patients and healthy controls using Human Clariom D Affymetrix chips, suitable to 
detect rare and low-expressing transcripts otherwise unnoticed by common sequencing 
methodologies. Network analysis identified lncRNAs targeting highly connected genes 
in the PsA transcriptome. Such genes are involved in molecular pathways crucial for 
PsA pathogenesis, including immune response, glycolipid metabolism, bone remodeling, 
type 1 interferon, wingless related integration site, and tumor necrosis factor signaling. 
Selected lncRNAs were validated by RT-PCR in an expanded cohort of patients. Moreover, 
modulated genes belonging to meaningful pathways were validated by RT-PCR in PsA 
PBMCs and/or by ELISA in PsA sera. The findings indicate that lncRNAs are involved in 
PsA pathogenesis by regulating both microRNAs and genes and open new avenues for 
the identification of new biomarkers and therapeutical targets.
Keywords: psoriatic arthritis, gene expression, long non-coding rnas, gene module, protein–protein interaction 
network
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inTrODUcTiOn
Psoriatic arthritis (PsA) is a chronic, immune-mediated, asym-
metric inflammatory arthritis characterized by inflammation 
at tendon or ligament insertion sites into bone (enthesitis) and 
by synovitis, eventually leading to joint erosions and new bone 
formation (1).
Up to 30% of patients with skin psoriasis may develop PsA and 
its prevalence is estimated in 1% in the general population. PsA 
shares genetic and clinical features with other forms of seronega-
tive spondyloarthritis (2, 3). Diagnostic criteria for PsA have not 
been validated, but the Classification Criteria for PsA (CASPAR 
criteria), published in 2006, define PsA for the purpose of enroll-
ing patients in clinical trials and provide guidance to clinicians 
(4, 5). Therefore, the diagnosis of PsA is mainly performed on 
clinical features after the exclusion of other seronegative arthriti-
des and no diagnostic tests are available so far.
The pathogenesis of PsA is still poorly understood and both 
autoinflammation and autoimmunity are believed to play a piv-
otal role in the disease. Synovial tissue in PsA is characterized by 
T-cell infiltrate, by marked angiogenesis, and by synovial hyper-
plasia with increased secretion of cytokines and proteases, which 
may amplify the local inflammatory process eventually leading 
to joint destruction (6). Tumor necrosis factor-alpha (TNF-α) is 
a very important inflammatory mediator and has been implicated 
in the pathogenesis of articular damage in PsA (6). TNF-α inhibi-
tors are currently used in PsA treatment; however, a high per-
centage of PsA patients does not respond to TNF-α antagonists 
(1, 7). Therefore, other cytokines have recently become targets of 
biological agents, such as interleukin-12 (IL-12), interleukin-23 
(IL-23), and interleukin-17 (IL-17) (1, 7). Indeed IL-17 plays a 
fundamental role in disease development and progression (8).
We have reported the findings of the transcriptome analysis in 
paired synovial tissue and peripheral blood cells of patients with 
PsA (9). The upregulation of Th-17 cells related genes and of type I 
interferon (IFN) inducible genes in PsA patients strengthened 
the hypothesis that PsA has a strong autoimmune origin, since 
the coactivity of type I IFN and IL-17 pathways is typical of 
autoimmunity (9). Moreover, we confirmed these findings with 
a miRNA microarray analysis in PBMCs of PsA patients showing 
that pathway enrichment analysis on gene targets of deregulated 
microRNAs (miRNAs) revealed signaling pathways typically 
implicated in PsA, such as TNF, mitogen-activated protein (MAP) 
kinase, and wingless related integration site (WNT) cascades (10).
By this study we wanted to provide a more in-depth knowledge 
on the epigenetic mechanisms that regulate the PsA pathogenesis 
by analyzing the expression profiles of long non-coding RNAs 
(lncRNAs) in the same cohort of patients that we studied in 
our previous work (10). lncRNAs are important molecules that 
regulate gene expression through multiple mechanisms and are 
involved in immune and inflammatory pathways (11). As far 
as we know, no study has yet taken into consideration lncRNAs 
expression profiles in PsA patients and only a few data have been 
reported the deregulation of some lncRNAs in psoriasis (12, 13).
Moreover, in this study we offer a sophisticated and integrated 
analysis of lncRNAs, miRNAs, and gene expression profiles in PsA 
patients that allows to identify lncRNAs that regulate transcripts 
effectively modulated in the disease and that are involved in 
pathogenetically relevant molecular pathways.
MaTerials anD MeThODs
Patients
We studied a cohort of 10 patients (6 males and 4 females, 
mean age: 53.5 years) affected by PsA, attending the Unit of 
Autoimmune Diseases, at the University Hospital of Verona, Italy. 
All patients fulfilled the CASPAR criteria for the diagnosis of 
PsA: inflammatory musculoskeletal involvement combined with 
at least three features: (1) evidence of current psoriasis, personal 
history of psoriasis, and family history of psoriasis in unaffected 
patients; (2) affected nails (onycholysis and pitting); (3) dactylitis; 
(4) negative rheumatoid factor (RF); and (5) radiographic evidence 
of new juxta-articular bone formation (excluding osteophytes) 
(4). All the patients underwent clinical examination and labora-
tory evaluation comprehensive of inflammatory markers, such as 
C-reactive protein and erythrocytes sedimentation rate; RF and 
anti-cyclic citrullinated peptide antibody detected by ELISA test; 
antinuclear antibody detected by indirect immunofluorescence 
on HeLa-derived HEp-2 cells; and genetic screening for the asso-
ciation with the allele HLA-B27. All patients underwent the fol-
lowing instrumental investigations: ultrasonography with Power 
Doppler to investigate subclinical enthesopathy and synovitis 
in asymptomatic patients, conventional radiography, magnetic 
resonance imaging, and scintigraphy. The radiological features of 
peripheral PsA included asymmetric distribution, participation 
of distal interphalangeal joints, periostitis, bone density preserva-
tion, bone ankylosis, and pencil-in-cup deformity.
The patients were affected by cutaneous or nails psoriasis and 
were enrolled in the study at diagnosis of peripheral PsA before 
starting immunosuppressive treatment.
All the participants to the study signed a written informed con-
sent and the local Ethical Committee of the University Hospital 
of Verona, Verona, Italy, had approved the study protocol. All the 
investigations have been performed according to the principles of 
the Helsinki declaration.
Microarray analysis
Blood samples were collected in BD Vacutainer K2EDTA tubes 
using a 21-gauge needle. PBMCs were obtained upon stratifica-
tion on Lympholyte® cell separation density gradient (Cedarlane, 
Burlington, ON, Canada). PBMCs composition was similar 
between patients and controls. Total RNA extraction from PBMCs 
was performed with miRNeasy mini kit following manufacturer’s 
protocol (Qiagen GmbH, Hilden, Germany). 500  ng of total 
RNA were used for sample preparation starting from 5  ml of 
blood. cRNA preparation, samples hybridization and scanning 
were performed following the Affymetrix (Affymetrix, Santa 
Clara, CA, USA) provided protocols, by Cogentech Affymetrix 
microarray unit (Campus IFOM IEO, Milan, Italy). All samples 
were hybridized on Human Clariom D (Thermo Fisher Scientific) 
gene chip and were analyzed using the Transcriptome Analysis 
Console 4.0 software (Applied Biosystem, Foster City, CA, USA 
by Thermo Fisher Scientific, Waltham, MA, USA).
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The Human Clariom D arrays allow to interrogate more than 
540,000 transcripts sourced from the largest number of public 
databases starting from as little as 100 pg of total RNA.
The Signal Space Transformation-Robust Multi-Array Average 
algorithm was applied to background-adjust, normalize, and log-
transform signals intensity.
Relative gene expression levels of each transcript were vali-
dated applying a One-Way analysis of variance (p ≤ 0.01) and 
multiple testing correction. Coding genes and lncRNAs that 
displayed an expression level at least 1.5-fold different in the test 
sample versus control sample (p ≤ 0.01) were carried forward in 
the analysis.
The targets (including microRNAs and genes) of all the 
lncRNAs that satisfied the above-mentioned FC and p-value 
criteria were screened using NPInter v3.0.1 This database allows 
the efficient recovery of all lncRNAs interactions experimentally 
validated by high-throughput experimental technologies (14, 15).
The list of gene targets of miRNAs that were targeted by sig-
nificantly modulated lncRNAs was obtained using the FunRich 
database2 (16).
Protein–Protein interaction (PPi) network 
construction and network clustering
The Search Tool for the Retrieval of Interacting Genes (STRING 
version 10.53) was used to obtain PPIs pairs that were validated 
by experimental studies (17) and to construct the PPI networks. 
Network topological analysis was performed using the Cytoscape 
software4 (18).
High-flow areas (highly connected regions) of the network 
were detected using the MCODE plugin of Cytoscape, based on 
the thresholds of k-core = 3 and node score cutoff = 0.2.
gene Functional classification  
and enrichment analysis
Genes were functionally classified into canonical biological pro-
cesses (BPs) on the basis of the gene ontology (GO) annotations.5
Biological processes and Pathways enrichment analysis was 
performed employing FunRich (hypergeometric p-value ≤0.05).
real-Time Pcr
lncRNAs Modulated in PsA
For each sample, 500 ng of total RNA was treated with 1 unit of 
DNase I Amplification Grade (Invitrogen; Carlsbad, CA, USA) 
according to the manufacturer’s protocol. First-strand cDNA 
was generated using the SuperScript IV First-Strand Synthesis 
System (Invitrogen; Carlsbad, CA, USA) with random hexamers, 
according to the manufacturer’s protocol. Real-time PCR was 
performed in triplicate with PowerUp™ Sybr® Green reagent 
(Applied Biosystems; Foster City, CA, USA) in a QuantStudio 6 
Flex system (Applied Biosystems; Foster City, CA, USA). Relative 
1 http://www.bioinfo.org/NPInter/ (Accessed: November 16, 2017).
2 www.funrich.org/ (Accessed: December 15, 2017).
3 http://string-db.org/ (Accessed: February 06, 2018).
4 www.cytoscape.org (Accessed: February 15, 2018).
5 www.geneontology.org (Accessed: January 19, 2018).
expression levels were calculated for each sample after normali-
zation against the geometric mean of the housekeeping genes 
GAPDH and beta-actin (ACTB) expression. The ΔΔCt method 
was used for comparing relative fold expression differences. The 
data are expressed as fold changes with respect to healthy.
Genes Modulated in PsA
First-strand cDNA was generated using the SuperScript III 
First-Strand Synthesis System for RT-PCR Kit (Invitrogen), with 
random hexamers, according to the manufacturer’s protocol. 
PCR was performed in a total volume of 25  µl containing 1× 
Taqman Universal PCR Master mix, no AmpErase UNG, and 
2.5 µl of cDNA; pre-designed, gene-specific primers, and probe 
sets for each gene were obtained from Assay-on-Demande Gene 
Expression Products (Applied Biosystems).
Real-time PCR reactions were carried out in a two-tube 
system and in singleplex. The real-time amplifications included 
10  min at 95°C (AmpliTaq Gold activation), followed by 40 
cycles at 95°C for 15 s and at 60°C for 1 min. Thermocycling and 
signal detection were performed with 7500 Sequence Detector 
(Applied Biosystems). Signals were detected according to the 
manufacturer’s instructions and the relative expression levels 
were calculated as it has been previously described (9).
Detection of soluble Mediators  
in sera of Psa Patients
Serum levels of glypican-4, IFN-γ, Wnt-2, mTOR, TNF-α, SPD-1, 
NFKB p65, NOTCH1, omentin, and adiponectin were detected 
using commercially available ELISA kits that were supplied by 
antibodies-online (glypican-4, Wnt-2, and mTOR), LifeSpan 
BioSciences (TNF-α, NFKB p65, and omentin), IBL International 
(IFN-γ), R&D (adiponectin), and Ray Biotech (sPD-1).
Plasmid construction and luciferase 
reporter assay
The plasmids to knockdown LINC00909 and LINC00657 were 
purchased from GenePharma (Shanghai, China).
Human HEK (human embryonic kidney) 293 T cells (1.5 × 104) 
grown in a 96-well plate were co-transfected with 150 ng of empty 
vector, 50 ng of firefly luciferase reporter comprising the lncRNAs 
mut vectors, (Promega, Madison, WI, USA) using Lipofectamie 
2000 (Invitrogen, USA). Cells were harvested 48  h after trans-
fection and analyzed using the Dual-Luciferase Reporter Assay 
System (Promega) according to the manufacturer’s protocol.
resUlTs
high-Throughput long non-coding  
rna and gene expression Profiling  
in Peripheral Blood Mononuclear  
cells of Psa
In order to evaluate the potential role played by lncRNAs in PsA 
pathogenesis, we performed a gene array study using the Clariom D 
human gene chip that enabled us to analyze, at the same time, 
both conventional gene and lncRNA expression profiles.
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We compared the lncRNA expression profiles of PBMC 
samples obtained from 10 PsA patients with 10 PBMC samples 
obtained from age and sex matched healthy donors and we found 
that 259 lncRNAs satisfied the Bonferroni-corrected p value crite-
rion (p ≤ 0.01) and the fold change criterion (FC ≥ |1.5|), display-
ing robust and statistically significant variation between PsA and 
healthy controls samples (Table S1 in Supplementary Material). 
The study was implemented by the analysis of conventional gene 
expression profiles in the same PsA samples and we found that 
1,922 differently expressed genes satisfied the above-mentioned 
criteria. The complete list of modulated genes can be found in 
Table S2 in Supplementary Material. In both cases, the arrays were 
validated by real-time PCR. LncRNAs LUCAT1 and TRIM55-1 
were validated by real-time PCR in the entire series of patients 
analyzed. Significantly different expression levels were found for 
all tested lncRNAs in PsA as compared to healthy controls (see 
Figure S1 in Supplementary Material).
Moreover, real-time PCR analysis for seven lncRNAs was 
carried out in an expanded panel of PsA patients (20 patients) 
and healthy controls (20 subjects). A significant modulation of all 
these lncRNAs was found in all tested patients thus confirming 
gene array results (see Figure 1).
To gain meaningful insights on the potential role played by 
modulated lncRNAs in PsA pathogenesis, the complete list of 
modulated lncRNA was filtered, extracting only those tran-
scripts for which a bona fide target annotations was present in 
NPInter. By this method 92 lncRNAs were selected (Table S3 in 
Supplementary Material) and, simultaneously, the list of all gene 
and microRNA targets of the selected lncRNAs, experimentally 
validated by high-throughput technologies, was extracted from 
the same database.
To corroborate our results we narrowed down our analysis 
to modulate lncRNA that targeted genes that were significantly 
modulated in the array and miRNAs that we found deregulated 
in our previous analysis of PsA PBMCs from the same cohort of 
patients (10) (Table 1). In particular, we found that 15 of these 
miRNAs modulated in PsA (hsa-miR-130a-3p, hsa-miR-148a-3p, 
hsa-miR-151a-5p, hsa-miR-17-5p, hsa-miR-186-5p, hsa-miR-
199a-3p, hsa-miR-199a-5p, hsa-miR-28-5p, hsa-miR-3135b, 
hsa-miR-320c, hsa-miR-320d, hsa-miR-331-3p, hsa-miR-423-5p, 
hsa-miR-451a, and hsa-miR-92a-3p) were targeted by selected 
lncRNAs. We then extracted from the FunRich database the 
annotated gene targets of the above-mentioned miRNAs select-
ing only transcripts that also resulted when modulated in the 
Clariom D array (Table S4 in Supplementary Material). Table 2 
recapitulates the above-selected lncRNAs and targets.
In summary, we selected only those lncRNAs, that targeted 
miRNAs and genes with evidence of modulation in our PsA sam-
ples to trace, with a good confidence, lncRNAs–miRNAs–genes 
interactions that are expected to be established in the course of PsA.
To validate our results we conducted a LINC00909siRNA and 
a LINC00657siRNA silencing in human 293 T cells, to explore 
whether this knockdown altered the expression levels of selected 
miRNAs targeted by LINC00909 (miR-148a-3p and mir-28-5p) 
and by LINC00657 (miR-130a-3p and miR-17-5p). We observed 
that the silencing of the two lncRNAs significantly increased the 
level of expression of their targeted miRNAs.
The registered percentages of increase were: 70 ±  3.8 and 
78  ±  1.4% for miR-148a-3p and mir-28-5p, respectively, and 
75  ±  2.3 and 80  ±  1.53% for miR-130a-3p and miR-17-5p, 
respectively.
PPi network of Modulated lncrnas in Psa
The lncRNA expression profiling of PsA PBMCs was integrated 
with a network analysis. We, therefore, inspected, by a bioin-
formatic methodology, all the functional and experimentally 
validated interactions among the protein products of genes tar-
geted by lncRNAs and by the 15 above-mentioned miRNAs (230 
genes) that were selected as previously described. Then, taking 
in account of these interactions, we constructed a PPI network 
which showed a good PPI enrichment p-value (0.00041). In the 
obtained network 229 of the above-mentioned genes (nodes), 
were connected by 195 pairs of interactions (edges). Since 229 
out of 230 of lncRNAs and miRNAs gene targets that we used 
as input for the network analysis, resulted connected in the PPI 
network, we could observe that the selected lncRNAs may act in 
an integrated fashion in the disease.
We then imported in Cytoscape the PPI network, adding to 
its scaffold the lncRNAs-genes, miRNAs-genes, and lncRNAs–
miRNAs interactions that we selected as we explained above. 
Thus, we obtained an implemented network that is showed in 
Figure 2. A topological analysis of this network was performed to 
highlight lncRNAs that were highly connected to the PPI network 
genes (i.e., targeting a large number of PPI-network genes) also 
considering all the lncRNA–gene interactions mediated by the 
selected miRNAs (i.e., lncRNA–miRNA–gene interactions). 
By this approach we could select seven lncRNAs, including 
EPB41L4A-AS1, LA16c-360H6.3, LINC00657, LINC00909, 
RP11-1100L3.8, RP11-539L10.3, and RP11-403I13.5 that 
displayed the highest connectivity in the network. As shown 
in Figures 3A–G (where genes of the PPI network are ordered 
around a circle based on their degree of connectivity, i.e., number 
of edges) the above-mentioned lncRNAs directly or indirectly 
targeted genes that, in most cases, were distributed in areas of 
the network characterized by a high degree of connectivity. This 
observation indicated that, since these lncRNAs targeted highly 
interconnected genes, they may have a broad effect in the disease 
that goes beyond the modulation of single target gene(s).
Modular analysis of genes and lncrnas 
Modulated in Psa
In a second part of our analysis we wanted to dissect the global 
impact of lncRNAs on the entire PsA transcriptome (i.e., on the 
1,922 modulated genes in PsA). Since the targeting of genes with 
more interacting partners may have a broader impact on the 
global transciptome than the modulation of few isolated genes, 
we aimed to inspect if the modulated lncRNAs may display con-
nections with highly interacting genes in PsA. To this purpose, 
we built the PPI network that included the protein products of 
all modulated genes in PsA that showed experimentally validated 
interactions obtaining a wide network containing 1,637 nodes 
and 9,415 edges and showing a very good PPI enrichment p-value 
(p < 10–16). Then we performed a modular analysis to find areas 
FigUre 1 | Expression of selected long non-coding RNAs in an expanded panel of psoriatic arthritis patients (20 patients) and healthy controls (20 subjects).  
Bars indicate SD.
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of the network that included the most highly connected genes 
(modules). By this analysis we could extract 16 modules (M1–M16, 
see Table S5 in Supplementary Material). All the 16 modules 
were imported in Cytoscape along with all the previously selected 
interactions with miRNAs and modulated lncRNAs that we also 
considered in the network analysis described in the previous 
paragraph. The graphical visualization of genes connected in 
modules and their interactions with lncRNAs showed that the 
majority of the 16 modules (10/16) were directly or indirectly 
targeted by modulated lncRNAs, including M1, M2, M4, M5, 
TaBle 1 | Selected modulated long non-coding RNAs in psoriatic arthritis patients versus healthy controls.
iD Fold change p-value gene symbol mrna accession
TC0500008318.hg.1 −2.37 0.0026 EPB41L4A-AS1 ENST00000413221.2
TC0700007000.hg.1 −2.02 0.0015 HOTAIRM1 ENST00000616712
TC0600008510.hg.1 −2.25 0.0087 KCNQ5-IT1 ENST00000445310
TC0700013567.hg.1 2.05 0.0013 LINC00174 ENST00000416366
TC0700007277.hg.1 2.46 0.0001 LINC00265 ENST00000340510.4
TC1500007707.hg.1 −1.58 0.0089 LINC00593 ENST00000558385.1
TC2000008995.hg.1 −2.27 0.0017 LINC00657 ENST00000565493
TC1800009043.hg.1 −1.84 0.0025 LINC00909 ENST00000577806
TC0200007199.hg.1 2.27 0.0007 LINC00486 ENST00000414054
TC0100009691.hg.1 −1.97 0.0003 RP11-403I13.5 ENST00000443018.1
TC0200010127.hg.1 −3.24 <0.0001 RP11-171I2.4 ENST00000605334.1
TC0200011420.hg.1 −2.68 0.0005 AC133528.2 ENST00000433036.1
TC0400009914.hg.1 −2.37 0.0027 RP11-539L10.3 ENST00000513179.1
TC0500009465.hg.1 −1.74 0.007 RP11-779O18.3 ENST00000523005.1
TC0800007847.hg.1 −14.9 <0.0001 AC084082.3 ENST00000517961.2
TC1100011278.hg.1 1.91 0.0003 RP11-867G23.3 ENST00000501708.1
TC1200006772.hg.1 −1.86 0.0044 RP11-75L1.1 ENST00000541404.1
TC1200010732.hg.1 −3.11 0.0058 RP11-1100L3.8 ENST00000564363.1
TC1400006719.hg.1 −2.54 0.0066 RP11-468E2.5 ENST00000558478.1
TC1400009275.hg.1 −1.61 0.0027 RP11-930O11.2 ENST00000560296.1
TC1600009188.hg.1 2.21 0.0021 LA16c-360H6.3 ENST00000574245.1
TC1700007241.hg.1 2.64 0.0008 RP11-283C24.1 ENST00000578585.1
TC2100007843.hg.1 −1.78 0.0016 AF131217.1 ENST00000430247.1
TC2200008462.hg.1 −3.38 0.0058 RP3-430N8.10 ENST00000602955.1
TC1500010312.hg.1 −2.52 0.0064 RP11-815J21.2 ENST00000561409.1
TC1800007426.hg.1 −3.49 0.0032 RP11-1151B14.4 ENST00000591360.1
TC1900011833.hg.1 1.81 0.0031 CTB-25B13.12 ENST00000588225.1
TC1900007159.hg.1 −1.77 0.0084 CTB-55O6.10 ENST00000590715.1
TC1200008393.hg.1 −1.74 0.0028 RP11-981P6.1 ENST00000552778.1
TC1200008425.hg.1 −2.1 0.0024 RP11-796E2.4 ENST00000499685.2
TC1400009962.hg.1 −2.61 0.0006 RP11-471B22.2 ENST00000555853.1
TC1600006833.hg.1 2.16 0.0024 RP11-77H9.5 ENST00000564919.1
TC1400009667.hg.1 1.88 0.0092 RP4-693M11.3 ENST00000557304.1
TC1000009009.hg.1 −1.6 0.0098 RP11-498B4.5 ENST00000433600.1
TC1400010386.hg.1 1.71 0.0064 CTD-3051D23.4 ENST00000553344.2
TC1200008527.hg.1 −2.91 0.0065 RP11-256L6.3 ENST00000551849.1
TC0200007485.hg.1 1.61 0.0048 AC016722.4 ENST00000429761.1
TC1400007302.hg.1 1.95 0.0041 CTD-2002H8.2 ENST00000557322.1
TC0500008150.hg.1 −2.4 0.0066 CTD-2260A17.1 ENST00000512856.1
TC0600010636.hg.1 −1.89 0.0005 RP3-406P24.3 ENST00000415144.1
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M8, M10, M11, M12, M14, and M15 (Figure 4). Moreover, we 
could observe that the vast majority of modules was targeted 
by the above-mentioned lncRNAs that included LINC00909 
(targeting 9/10 modules) LINC00657 (targeting 8/10 modules), 
EPB41L4A-AS1, RP11-539L10.3 (targeting 7/10 modules), 
LA16c-360H6.3, RP11-403I13.5, and RP11-1100L3.8 (targeting 
5/10 modules) (Table S6 in Supplementary Material).
Functional analysis of the Targeted 
Modules and Their Targeting lncrnas
To dissect the possible role played by the module-targeting- 
lncRNAs we performed a functional classification of genes 
included in the 10 targeted modules, based on the GO classifica-
tion criteria. Figure 5 recapitulates all the most relevant GO BPs 
in which the genes of targeted modules are classified.
M1 was the most targeted module and 35 lncRNAs showed 
direct or indirect connections with it (see Table S6 in Supple-
mentary Material). The 88 genes included in this module were 
mostly related to translation, mRNA splicing, and protein 
ubiquitination GO BPs. Among genes included in protein ubiqui-
tination, nine genes belonged to the “proteasome-mediated 
ubiquitin-dependent protein catabolic process” BP, including 
CUL1, CUL3, FBXW5, FBXW7, FBXL19, HECTD3, NEDD4L, 
RNF126, and UBE2A. Interestingly, it has been recently observed 
that ubiquitin–proteasome-mediated protein degradation plays a 
role in modulating the balance between bone formation and bone 
resorption, since it is involved in signaling pathways that are crucial 
for bone homeostasis like RANK/NF-κB pathway and the Wnt/β-
catenin pathway (19). In addition CUL3 is also associated with the 
“Wnt signaling pathway” BP. 12 genes were targeted in the M1, 
including CUL5, TRA2B, SRRM1, ASB6, HNRNPUL1, CPSF7, 
HNRNPC, NUDT21, UPF1, and the above-mentioned FBXL19, 
NEDD4L, and FBXW7. UPF1 was the most targeted gene in M1. It 
is critical for the activity of Regnase-1 also called MCPIP1 (mono-
cyte chemotactic protein-1-induced protein-1), a crucial molecule 
that regulates immune response avoiding over-activation of the 
immune system (20). Interestingly, the gene FBXL19 represents 
TaBle 2 | Long non-coding RNAs (LncRNAs) and their targets modulated in 
psoriatic arthritis.
lncrnas gene targets mirna targets
LINC00174 CPSF7
LINC00265 IGF2BP2
LINC00593 UPF1
LINC00657 CPSF7, FXR1, HNRNPC, NUDT21 
UPF1, ZC3H7B
hsa-miR-130a-3p
hsa-miR-17-5p
hsa-miR-186-5p
hsa-miR-199a-3p
hsa-miR-199a-5p
hsa-miR-28-5p
hsa-miR-320c
hsa-miR-320d
hsa-miR-331-3p
hsa-miR-423-5p
hsa-miR-451a
LINC00909 UPF1 hsa-miR-130a-3p
hsa-miR-148a-3p
hsa-miR-28-5p
hsa-miR-320c
hsa-miR-320d
LINC00486 FXR1, UPF1
EPB41L4A-AS1 CPSF7, UPF1 hsa-miR-130a-3p
hsa-miR-17-5p
HOTAIRM1 CPSF7, UPF1
KCNQ5-IT1 CPSF7, UPF1
RP11-403I13.5 hsa-miR-92a-3p
RP11-171I2.4 CPSF7
AC133528.2 CPSF7
RP11-539L10.3 hsa-miR-148a-3p
hsa-miR-199a-3p
RP11-779O18.3 HNRNPC, UPF1, ZC3H7B
AC084082.3 CPSF7, NUDT21, UPF1 hsa-miR-331-3p
RP11-867G23.3 UPF1, IGF2BP2
RP11-75L1.1 UPF1
RP11-1100L3.8 UPF1 hsa-miR-17-5p
hsa-miR-423-5p
RP11-468E2.5 UPF1
RP11-930O11.2 UPF1
LA16c-360H6.3 IGF2BP2 hsa-miR-17-5p
RP11-283C24.1 UPF1
AF131217.1 UPF1
RP3-430N8.10 hsa-miR-331-3p
RP11-815J21.2 hsa-miR-186-5p
RP11-1151B14.4 UPF1
CTB-25B13.12 UPF1
CTB-55O6.10 CPSF7, UPF1
RP11-981P6.1 CPSF7, UPF1, ZC3H7B
RP11-796E2.4 UPF1 hsa-miR-3135b
RP11-471B22.2 CPSF7, IGF2BP2, UPF1, ZC3H7B
RP11-77H9.5 CPSF7, HNRNPC, IGF2BP2, UPF1
RP4-693M11.3 UPF1
RP11-498B4.5 UPF1
CTD-3051D23.4 IGF2BP2
RP11-256L6.3 NUDT21, UPF1
AC016722.4 CPSF7, UPF1, ZC3H7B
CTD-2002H8.2 CPSF7, HNRNPC, NUDT21, UPF1, 
ZC3H7B
CTD-2260A17.1 hsa-miR-151a-5p
RP3-406P24.3 CPSF7
7
Dolcino et al. LncRNAs Expression Profiling in PsA
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1533
M2 was targeted by 6 lncRNAs and included 40 genes that 
were mainly involved in cell division, inflammatory response (i.e., 
CCR7, CXCR1, CXCR2, PF4, and PPBP/CXCL7), tumor necrosis 
factor (TNF)-mediated signaling pathway (i.e., TNFRSF1B, 
TNFSF12, TNFRSF12A, and PSMA7), and Wnt signaling path-
way (i.e., AXIN1, DVL3, GNB2, PPP2R5C, PSMA4, PSMB1, 
PSMC4, PSMD4, and RNF146) BPs. Interestingly, the expression 
of CXCL7 is increased in Rheumatoid arthritis (AR) synovia (23). 
Moreover AXIN2 another gene included in M2 is related to the 
intramembranous ossification BP. Eight genes were targeted in 
M2, including ADCY3, GNAI1, PSME3, PSMF1, RELA, TRAF3, 
and the above-mentioned TNFRSF1B and CCR7. In particular, 
the expression of CCR7 is stimulated by TNF-α and interleu-
kin 1-beta in osteoclasts (24). Moreover, RELA is involved in 
peripheral regulatory T cell-induced tolerance (25) and TRAF3 
is required for T cell and invariant natural killer T cell effector 
functions (26). In addition, TRAF3 is also involved in limiting 
osteoclastogenesis, indeed RANKL-induced degradation of 
TRAF3 enhances TNF-induced osteoclastogenesis (27).
M4 was targeted by seven lncRNAs and included 57 genes that 
were mainly involved in cell division, DNA repair, endocytosis, 
mitochondrial translation, mRNA export from nucleus, regula-
tion of glycolytic process, and transcription. In addition, this 
module included two genes (i.e., MRE11A and XRCC6) associated 
with the BP “positive regulation of type I interferon production” 
and the gene POU2F2/OCT2 that increases the differentiation 
of antibodies secreting activated B cells (28). In this module the 
genes GBF1, MYBL2, RAD23A, and WASL were targeted.
M5 was targeted by the RP11-403I13.5 lncRNA and included 
19 genes. Protein targeting to ER and translation were the most 
represented BPs in this module.
M8 was targeted by four lncRNAs (EPB41L4A-AS1, LINC00657, 
LINC00909, and RP11-539L10.3) and in this module seven genes 
were connected, including BRPF3, TAF12, TAF2, TAF7, TBPL1, 
TRIM24, and BPTF almost associated with the “translation” BP. 
Among these, BPTF is important for the homeostasis of T cells 
and is crucial for the maintenance and function of regulatory 
T (Treg) cells (29).
M10 was targeted by 8 lncRNAs and included 49 genes. These 
genes were associated with many BPs, including cell proliferation, 
signal transduction, transcription, Wnt signaling pathway (i.e., 
BCL9L, FZD6, LRP6, ATP6V0C, BCL9, and PYGO2), vasculo-
genesis (i.e., ENG and TGFBR2), bone resorption (i.e., TCIRG1), 
negative regulation of bone mineralization (i.e., SRGN), osteo-
blast differentiation (i.e., LGR4), and osteoblast development 
(i.e., LRP5). Several genes were associated with BPs related to 
glucose homeostasis like, for example, PPARGC1A (cellular glu-
cose homeostasis), GSK3A (cellular response to insulin), IGF1R 
(insulin receptor signaling pathway), RAF1 (insulin secretion), 
and RAP1A (positive regulation of glucose import). In addition 
other genes were classified into BPs related to adaptive immune 
response like T  cell differentiation (i.e., RIT1 and TCF7), and 
T  cell cytokine production (KDELR1) and B  cell homeostasis 
(SOS1). In M10 12 genes were targeted, including SHOC2, 
CCNL1, CDK13, MED16, MMS19, and the above-mentioned 
FZD6, PYGO2, KDELR1, PPARGC1A, RAP1A, SOS1, and 
TGFBR2.
a susceptibility locus for PsA (21). Finally, other two genes of 
M1, TRIM32, and HERC5 play a role in the innate immune 
response and, in particular, HERC5 activates IRF3 (22).
FigUre 2 | Protein–protein interaction (PPI)-network of differently expressed genes in psoriatic arthritis (PsA) targeted by the selected long non-coding  
RNAs and microRNAs modulated in PsA.
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M11 was targeted by 2 lncRNAs and included 28 genes. 
A large number of these genes were assigned to “lipid metabolic 
process” (i.e., PLCD3, PPAP2B, SLC27A1, and TBL1X), “phos-
pholipid metabolic process” (i.e., AGPAT2, LPCAT3, LPCAT4, 
and PPAP2C), and to “phosphatidylinositol biosynthetic process” 
(CDIPT, MTMR14, PI4K2B, and PIK3C2B) BPs. Interestingly, 
two genes namely CARM1 and FASN were associated with 
“endochondral bone morphogenesis” and “osteoblast differentia-
tion” BPs, respectively. In this module, TERF2, YPEL3, and the 
above-mentioned MTMR14 were targeted.
M12 was targeted by 6 lncRNAs and included 30 genes. We 
observed that several genes of this module classified in BPs 
related to the immune response, including SPI1/PU.1 (lymphoid 
progenitor cell differentiation), CD244 and KLRF1 (innate 
immune response), CD226 (positive regulation of natural killer 
cell cytokine production), CD7 (T  cell activation), CD247 
(T cell receptor signaling pathway), GBP1 (regulation of T cell 
receptor signaling pathway), CD79A (B cell activation), GBP1, 
GBP2, and CIITA (type I interferon signaling pathway), HCST, 
LILRB2, and KLRB1 (regulation of immune response), GZMA 
(immune response) and SPI1/PU.1 (lymphoid progenitor cell 
differentiation), and CIITA (positive regulation of MHC class I 
and of MHC class II biosynthetic process). In particular, the 
transcription factor SPI1/PU.1 is crucial for the development of 
interleukin-9-producing helper T cells (Th9) (30, 31) that have 
been recently involved in the PsA pathogenesis (32).
Moreover five genes, including DAG1, COL14A1, LAMA2, 
LAMA3, and LAMC1 were associated with the “extracellular 
matrix organization” BP. LAMA3 and FAM168B were targeted 
in this module.
M14 was targeted by three lncRNAs and included 14 genes that 
were mainly associated with protein targeting to mitochondrion 
(TOMM20 and TOMM40), protein import into mitochondrial 
inner membrane (TIMM22), ATP biosynthetic process (ATP5I), 
apoptosis (BCL2L11 and CASP4), and in Wnt signaling pathway 
(TLE1 and TLE3) BPs. In this module the genes BCL2L11 and 
VDAC1 were targeted.
Finally, M15 was targeted by 6 lncRNAs and included 44 genes. 
In this module, we observed the presence of genes classified in 
several BPS, including cell division (TUBA1C, TFDP1, CEP192, 
FigUre 3 | Protein–protein interaction (PPI) network of differently expressed genes targeted by selected microRNAs and long non-coding RNAs (lncRNAs). 
Graphical representation of the connections among genes in the PPI network and EPB41L4A-AS1 (a), LA16c-360H6.3 (B), LINC00657 (c), LINC00909 (D), 
RP11-1100L3.8 (e), RP11-539L10.3 (F), and RP11-403I13.5 (g). In the PPI network all genes are ordered around a circle based on their degree of connectivity 
(i.e., number of edges). Genes directly or indirectly targeted by the lncRNAs are highlighted in yellow.
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CEP63, and MAPRE1) glycolytic process (PFKL, PFKM, and 
PKM), Wnt signaling pathway (MARK2, CTNNBIP1, EIF2C1, 
and TNRC6C), osteoblast differentiation (ASF1A and MAPK11), 
and regulation of type I interferon-mediated signaling pathway 
(CDC37). Genes targeted in this module were: AHNAK, CALB1, 
CCT6A, CEP63, CEP97, GAB1, MAPRE1, PFKM, and TNRC6C.
CALB1 plays a role in differentiation and matrix formation in 
osteoblasts (33), GAB1 is important for normal postnatal bone 
FigUre 4 | Gene modules that are targeted by the selected long non-coding RNAs (lncRNAs) modulated in psoriatic arthritis. In each module (M) genes  
are represented by light blue rectangles whereas targeting microRNAs and lncRNAs are represented by orange and yellow rectangles, respectively.
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FigUre 5 | Functional classification of genes included in the targeted modules. Graphical representation of long non-coding RNAs targeting the gene modules  
and of the most relevant biological processes (BPs) in which genes in each module can be classified. The BPs are represented by colored circles (each color 
corresponds to a different BP). The size of circles does not correspond to the number of genes that are classified in each BP.
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homeostasis (34) and MAPRE1 regulates cell–cell adhesion-
induced osteoblast differentiation (35).
Since disease can be viewed as the result of perturbations of 
complex signaling networks, a pathway enrichment analysis was 
performed, in each module, using FUnrich. This analysis showed 
that the most represented enriched pathways were related to 
immune response (including signaling of both adaptive and 
innate immune response, type I interferon and gamma interferon 
signaling), bone homeostasis, metabolism, and cell adhesion.
The results obtained are shown in Figure  6, which shows a 
schematic representation of the most relevant enriched signaling 
pathways (p ≤ 0.05).
To provide experimental evidence that pathways identified by 
the throughput analysis of modulated genes and lncRNAs in PsA 
are active in the disease, we performed a two step validation of 
the presented results. Indeed, first we validated by real-time PCR 
the modulation of genes ascribed to several signaling pathways, 
including SH3GL1, EPN1, and NUP214 (mTOR signaling), 
TRAF2, TNFRSF1B, and RELA (TNF/NF-κB signaling), MAPK7 
and MAPK11 (toll-like receptors signaling), TCF7, BCL9, and 
LRP6 (Wnt signaling), MED15, ENG, and ACTN4 (glypican 
signaling), GSK3A, IGF1R, and PARGC1A (insulin signaling), 
and CIITA IFI27 and MYD88 (type I interferon signaling). All 
the tested transcripts were overexpressed in PsA patients when 
compared to healthy subjects (see Figure S2 in Supplementary 
Material).
Second, in the sera of patients with PsA, we evaluated the 
presence of several molecules associated with the pathways 
modulated in PsA. Indeed, we decided to quantify the serum 
levels of glypican-4, IFN-γ, Wnt-2, mTOR, TNF-α, sPD-1, NFKB 
p65, NOTCH1, omentin, and adiponectin. Figure  7 shows the 
concentration of these molecules in the sera of the PsA patients. 
The serum levels of all the tested molecules were significantly 
increased in PsA patients when compared to healthy donors with 
the exception of adiponectin and omentin that were significantly 
decreased in PsA sera.
DiscUssiOn
Psoriatic arthritis is a chronic inflammatory arthritis that affects 
10–30% of patients with skin psoriasis. IL-17, TNF-α, and type I 
IFNs play a fundamental role in the pathogenesis of the disease 
and monoclonal antibodies targeting IL-17 and TNF-α along 
with IL-12/IL-23 are the main biotechnological treatments that 
have a dramatic good response in PsA and in skin psoriasis. As we 
have previously reported (9), the involvement of the mentioned 
cytokines is typical of an autoimmune process and support the 
hypothesis of the autoimmune origin of the disease. In particular, 
IL-17 is able to synergize with TNF-α, IL-22, and other cytokines, 
including IL-6 and IL-8, in sustaining the inflammatory process 
at different sites and in favoring the development of comorbidities 
that are typical of psoriasis, such as PsA, metabolic syndrome, 
obesity, and cardiovascular disease.
Long non-coding RNAs control gene expression at multiple 
levels, including epigenetic regulation, chromatin remodeling, 
and post-transcriptional gene regulation. Accumulating evidences 
indicate that lncRNAs can be involved in different types of 
immune-mediated human diseases, including autoimmune dis-
eases (11). The role played by lncRNAs in PSA pathogenesis has 
not been elucidated yet and a comprehensive analysis of lncRNA 
expression profiles in PsA has not been performed. We, therefore, 
aimed to identify lncRNA expression signatures associated with 
PsA, analyzing the expression of a vast array of lncRNA in PBMC 
cells from PsA patients by microarray analysis.
The applied criteria for the selection of modulated lncRNAs 
included a multiple step process that combined the lncRNAs 
expression analysis to the conventional gene expression and 
miRNAs profiling in the same cohort of patients.
By this approach we were able to select deregulated lncRNAs 
that were as much as possible correlated to the PsA transcriptome.
Through a complex network analysis of the whole set of 
molecular interactions among modulated genes and lncRNAs 
we further wanted to select those lncRNAs that targeted modules 
of most highly connected genes in the PsA interactome, since 
they may have a major impact on PsA gene modulation. That, 
for example, has led us to favor lncRNAs with high connectivity 
rather than poorly connected lncRNAs (even) with higher fold 
change. The functional analysis of the above-mentioned highly 
connected modules revealed that the modulated lncRNAs tar-
geted genes involved in BPs that play a pivotal role in the PsA 
pathogenesis such as, for example, immune response (including 
B and T cell activation) inflammatory response, TNF, Wnt and 
type I interferon-mediated signaling, bone resorption, bone min-
eralization, and glyco-lipid metabolic process (see Results), thus 
indicating that the selected lncRNAs regulated the three major 
aspects of the disease, including skin involvement, osteo-articular 
features, and metabolic syndrome.
As it has recently acquired in molecular biology, diseases are 
now viewed in the context of signaling pathways perturbation. 
We, therefore, performed a pathway enrichment analysis of 
all targeted gene modules and, by this approach we reached a 
non-ambiguous identification of important pathways that can 
be modulated by the selected lncRNAs. Our analysis confirmed 
that these lncRNAs play a role in the regulation of signaling 
pathways associated with both adaptive and immune response 
and with autoimmune diseases (i.e., type I interferon signal-
ing pathway). In addition, they regulate important signaling 
involved in bone homeostasis including glypican, syndecan, 
and Wnt pathways.
Moreover, these results revealed the presence in PsA of 
lncRNAs that modulate the signaling pathway associated with 
influenza, thus highlighting the possible role played by influenza 
viruses in triggering PsA and suggesting the possible involvement 
of an epigenetic control. The selected lncRNAs were involved in 
the modulation of lipid metabolism pathway (see Results, module 
M11), and it is well known that dyslipidemia is frequently associ-
ated with PsA (36) and, in particular, patients with PsA have been 
shown to have elevated cholesterol levels (37) and increase risk of 
cardiovascular disease.
Another deregulated signaling pathway is the S6K1 (S6 kinase 1) 
and mTOR (mammalian target of rapamycin) pathway (see Results, 
modules M1, M4, and M5), a nutrient sensing system that respond 
to nutrient overload leading to insulin resistance, obesity, and dia-
betes (38, 39). These observations suggest that lncRNAs may also 
FigUre 6 | Biological processes and pathways enrichment analysis of the targeted modules. Selection of the different enriched pathways (p < 0.05)  
in the 10 targeted modules (M). Pathways that are enriched in more than one module are labeled by the same color in the different modules.
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FigUre 7 | Serum levels of selected molecules in psoriatic arthritis (PsA) patients and in normal subjects. The histograms represent the mean of the results 
obtained in 20 healthy donors and in 20 PsA patients.
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be involved in the metabolic syndrome frequently associated with 
PsA. Hyperuricemia is another feature of metabolic syndrome 
and is also known to be more frequent in psoriatic subjects than 
in the normal population. In humans, purines are metabolized 
into uric acid, which is a strong stimulator of innate immunity. In 
this regard, hyperuricemia may increase uric acid crystallization 
in and around joints, thereby inducing PsA in psoriatic subjects, 
thus representing an independent risk factor for PsA. Activation of 
pathways modulation of genes involved in related to nucleobase, 
nucleoside, nucleotide, and nucleic acid metabolism (modules 
M1, M4, and M8) may reflect this particular aspect of PsA.
Finally, lncRNAs control several pathways involved in cell 
adhesion (see Results, modules M4, M10, M11, M12, M14, and 
M15). The modulation of these pathways may contribute to the 
increased mucosal permeability of the gut that has been observed 
in PsA, even in the absence of bowel pathology (40). Indeed, 
bowel disease is six times more frequent in patients with PsA. 
Since an altered intestinal barrier is a feature of PsA, the presence 
15
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of gastrointestinal involvement in PsA should be carefully inves-
tigated during the diagnostic work up.
The detection of significantly different serum levels in PsA 
patients compared to healthy subjects of several soluble media-
tors, ascribed to the main pathways targeted by the selected 
lncRNAs, strongly suggests that they modulate signaling net-
works that are active in the disease. In particular, the increased 
serum levels of glypican-4 and the decrease of adiponectin 
and omentin highlight the typical metabolic aspects of PsA 
patients.
Indeed glypican-4 has been considered a novel adipokine that 
boosts insulin signaling and, interestingly glypican-4 levels are 
significantly increased in obese patients with insulin resistance 
(41). Moreover, both adiponectin and omentin have been showed 
decreased in sera from psoriatic patients (42, 43) and decreased 
levels of both molecules have been associated with, and involved 
in, metabolic syndrome (44, 45).
In conclusion, this study is the first report on lncRNAs that 
may exert an epigenetic control on PsA pathogenesis. The original 
approach that integrates genes and lncRNAs expression profiles 
presented in the study, allows to identify deregulated lncRNAs 
that modulate crucial molecular signaling associated with the 
typical features of the disease. These findings further support 
that PsA is an autoimmune disease with systemic inflammation 
associated with obesity and metabolic syndrome leading to 
cardiovascular disease.
Finally, we may suggest that these lncRNAs may be useful to 
design novel therapeutic strategies in PsA.
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TaBle s1 | Long non-coding RNAs modulated in psoriatic arthritis patients 
versus healthy subjects.
TaBle s2 | Genes modulated in psoriatic arthritis patients versus healthy subjects.
TaBle s3 | Long non-coding RNAs modulated in psoriatic arthritis patients 
versus healthy subjects with available target annotations.
TaBle s4 | Target genes of the selected microRNAs that are targeted by long 
non-coding RNAs modulated in psoriatic arthritis.
TaBle s5 | Genes modulated in psoriatic arthritis patients versus healthy 
subjects and included in the modules.
TaBle s6 | Long non-coding RNAs modulated in psoriatic arthritis that target 
modules.
FigUre s1 | Expression of selected long non-coding RNAs in psoriatic arthritis 
(PsA) patients by real-time PCR. Real-time PCR of LUCAT1 and lnc-TRIM55-1 in 
PsA and healthy samples included in the microarray. Bars indicate SD. *p < 0.05; 
**p < 0.01; Student t-test.
FigUre s2 | Expression by real-time PCR of genes involved in signaling 
pathways that are modulated in psoriatic arthritis patients compared to healthy 
subjects. Bars indicate SD.
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